307 related articles for article (PubMed ID: 33761116)
1. Margetuximab: First Approval.
Markham A
Drugs; 2021 Apr; 81(5):599-604. PubMed ID: 33761116
[TBL] [Abstract][Full Text] [Related]
2. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
3. Margetuximab in HER2-positive metastatic breast cancer.
Gradishar WJ; O'Regan R; Rimawi MF; Nordstrom JL; Rosales MK; Rugo HS
Future Oncol; 2023 May; 19(16):1099-1112. PubMed ID: 37170847
[TBL] [Abstract][Full Text] [Related]
4. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
Nur Husna SM; Wong KK
Mol Immunol; 2022 Dec; 152():45-54. PubMed ID: 36272249
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
[TBL] [Abstract][Full Text] [Related]
6. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
7. Margetuximab for the treatment of HER2-positive metastatic breast cancer.
Tarantino P; Morganti S; Uliano J; Giugliano F; Crimini E; Curigliano G
Expert Opin Biol Ther; 2021 Feb; 21(2):127-133. PubMed ID: 33238772
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab: first global approval.
Poole RM; Vaidya A
Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
[TBL] [Abstract][Full Text] [Related]
9. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS; Im SA; Cardoso F; Cortes J; Curigliano G; Musolino A; Pegram MD; Bachelot T; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Schwartz GN; Pluard TJ; Ricci F; Gwin WR; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Gal-Yam EN; Yerushalmi R; Fasching PA; Kaufman PA; Ashley EJ; Perez-Olle R; Hong S; Rosales MK; Gradishar WJ;
J Clin Oncol; 2023 Jan; 41(2):198-205. PubMed ID: 36332179
[No Abstract] [Full Text] [Related]
10. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
Royce M; Osgood CL; Amatya AK; Fiero MH; Chang CJG; Ricks TK; Shetty KA; Kraft J; Qiu J; Song P; Charlab R; Yu J; King KE; Rastogi A; Janelsins B; Weinberg WC; Clouse K; Borders-Hemphill V; Brown L; Gomez-Broughton C; Li Z; Nguyen TT; Qiu Z; Ly AT; Chang S; Gao T; Tu CM; King-Kallimanis B; Pierce WF; Chiang K; Lee C; Goldberg KB; Leighton JK; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Apr; 28(8):1487-1492. PubMed ID: 34916216
[TBL] [Abstract][Full Text] [Related]
11. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract][Full Text] [Related]
12. HER2 directed therapy for gastric/esophageal cancers.
Won E; Janjigian YJ; Ilson DH
Curr Treat Options Oncol; 2014 Sep; 15(3):395-404. PubMed ID: 24811128
[TBL] [Abstract][Full Text] [Related]
13. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
14. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
Bang YJ; Giaccone G; Im SA; Oh DY; Bauer TM; Nordstrom JL; Li H; Chichili GR; Moore PA; Hong S; Stewart SJ; Baughman JE; Lechleider RJ; Burris HA
Ann Oncol; 2017 Apr; 28(4):855-861. PubMed ID: 28119295
[TBL] [Abstract][Full Text] [Related]
15. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
17. Clinical development and current role of margetuximab for the treatment of breast cancer.
Tarantino P; Uliano J; Morganti S; Giugliano F; Crimini E; Curigliano G
Drugs Today (Barc); 2021 Sep; 57(9):551-558. PubMed ID: 34586103
[TBL] [Abstract][Full Text] [Related]
18. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
19. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
